Natera has charted another milestone, raising $180 million in an initial public offering to support its R&D work and bolster its footprint in cancer diagnostics.

Cash from the IPO helps Natera at a critical moment, as it looks to develop its noninvasive prenatal technology and diversify its portfolio. The company will funnel about $59.1 million in proceeds toward working capital and general corporate purposes, and will use another $100 million “for continued investments in research and development for our core technology and development of its product offerings.”

press release
article in FierceBiotech